Advertisement

Assessing the association between fluoroquinolones and emerging adverse drug reactions raised by regulatory agencies: An umbrella review

Published:January 23, 2020DOI:https://doi.org/10.1016/j.ejim.2020.01.009

      Highlights

      • Warnings concerning fluoroquinolone-associated adverse events were recently issued.
      • Umbrella review was performed to assess credibility and quality of evidence.
      • Credible and highly suggestive associations with AAD and ATD were found.
      • Weak evidence of causality for the association with retinal detachment emerged.
      • Limitations of both umbrella review and observational evidence exist.

      Abstract

      Background

      Regulatory agencies warned against fluoroquinolones for the management of minor infections because of the risk of emerging adverse events (collagen-associated adverse events, neuropsychiatric toxicity and long-term disability). We aimed to assess quality and credibility of evidence as well as causality regarding these putative associations.

      Methods

      MEDLINE, Scopus, Web of Science and PROSPERO were searched, from inception to August 2019, for systematic reviews with meta-analyses investigating emerging adverse events. Two investigators extracted data to grade quality (through validated AMSTAR-2 tool), rank credibility of the evidence (convincing, highly suggestive, suggestive, weak) through adapted criteria including E-value calculation, and assess causality (Hill's criteria).

      Results

      Seven systematic reviews of observational studies providing 16 risk estimates [seven, five and four, respectively, for aortic aneurysm/dissection (AAD), retinal detachment (RD) and any tendon disorders (ATD)] met inclusion criteria. No systematic reviews with meta-analysis investigating the risk of neuropsychiatric toxicity or long-term disability were found. The associations between fluoroquinolones and AAD/ATD showed highly suggestive credibility and were supported by strong evidence of causality (double increased risk, especially within first 2 months of treatment). Conflicting data concerning the emergence of RD were retrieved, resulting in weak evidence of causality. Quality of the evidence ranged from high to low for AAD, from moderate to critically low for RD, and it was moderate for ATD.

      Conclusion

      Our analysis supports credible, plausible and highly suggestive associations with AAD (rare occurrence but strong causality) and ATD. Limitations of both umbrella reviews and observational evidence should be considered.

      Graphical abstract

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hicks L.A.
        • Taylor T.H.
        • Hunkler R.J.
        U.S. outpatient antibiotic prescribing, 2010.
        N Engl J Med. 2013; 368 (Apr 11): 1461-1462
        • Kourlaba G.
        • Gkrania-Klotsas E.
        • Kourkouni E.
        • Mavrogeorgos G.
        • Zaoutis T.E.
        Antibiotic prescribing and expenditures in outpatient adults in Greece, 2010 to 2013: evidence from real-world practice.
        Euro Surveill. 2016; 21 (Jun 30)https://doi.org/10.2807/1560-7917.ES.2016.21.26.30266
        • Bätzing-Feigenbaum J.
        • Schulz M.
        • Schulz M.
        • Hering R.
        • Kern W.V.
        Outpatient antibiotic prescription.
        Dtsch Arztebl Int. 2016; 113 (Jul 1): 454-459
        • Vaughn V.M.
        • Gandhi T.
        • Conlon A.
        • Chopra V.
        • Malani A.N.
        • Flanders S.A.
        The association of antibiotic stewardship with fluoroquinolone prescribing in Michigan hospitals: a multi-hospital cohort study.
        Clin Infect Dis. 2019; (Feb 13Epub ahead of print)https://doi.org/10.1093/cid/ciy1102
        • Versporten A.
        • Zarb P.
        • Caniaux I.
        • Gros M.F.
        • Drapier N.
        • Miller M.
        • Jarlier V.
        • Nathwani D.
        • Goossens H.
        • Global-PPS network
        Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey.
        Lancet Glob Health. 2018; 6 (Jun): e619-e629
        • Redgrave L.S.
        • Sutton S.B.
        • Webber M.A.
        • Piddock L.J.
        Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success.
        Trends Microbiol. 2014; 22 (Aug): 438-445
        • Claeys K.C.
        • Hopkins T.L.
        • Vega A.D.
        • Heil E.L.
        Fluoroquinolone restriction as an effective antimicrobial stewardship intervention.
        Curr Infect Dis Rep. 2018; 20 (Mar, 23): 7
        • Poluzzi E.
        • Raschi E.
        • Motola D.
        • Moretti U.
        • De Ponti F.
        Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA adverse event reporting system.
        Drug Saf. 2010; 33 (Apr 1): 303-314
        • Sousa J.
        • Alves G.
        • Fortuna A.
        • Falcão A.
        Third and fourth generation fluoroquinolone antibacterials: a systematic review of safety and toxicity profiles.
        Curr Drug Saf. 2014; 9: 89-105
        • Owens R.C.
        • Ambrose P.G.
        Antimicrobial safety: focus on fluoroquinolones.
        Clin Infect Dis. 2005; 41 (Jul 15): S144-S157
        • Stahlmann R.
        • Lode H.M.
        Risks associated with the therapeutic use of fluoroquinolones.
        Expert Opin Drug Saf. 2013; 12 (Jul): 497-505
        • Teng C.
        • Walter E.A.
        • Gaspar D.K.S.
        • Obodozie-Ofoegbu O.O.
        • Frei C.R.
        Torsades de pointes and QT prolongation associations with antibiotics: a pharmacovigilance study of the FDA adverse event reporting system.
        Int J Med Sci. 2019; 16 (Jun 10): 1018-1022
        • Teng C.
        • Reveles K.R.
        • Obodozie-Ofoegbu O.O.
        • Frei C.R.
        Clostridium difficile infection risk with important antibiotic classes: an analysis of the FDA adverse event reporting system.
        Int J Med Sci. 2019; 16 (May 7): 630-635
        • Bennett A.C.
        • Bennett C.L.
        • Witherspoon B.J.
        • Knopf K.B.
        An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the food and drug administration and the European medicines agency.
        Expert Opin Drug Saf. 2019; 18 (Sep 18): 1055-1063
        • Tsai W.C.
        • Hsu C.C.
        • Chen C.P.
        • Chang H.N.
        • Wong A.M.
        • Lin M.S.
        • Pang J.H.
        Ciprofloxacin up-regulates tendon cells to express matrix metalloproteinase-2 with degradation of type I collagen.
        J Orthop Res. 2011; 29 (Jan): 67-73
        • Reviglio V.E.
        • Hakim M.A.
        • Song J.K.
        • O'Brien T.P.
        Effect of topical fluoroquinolones on the expression of matrix metalloproteinases in the cornea.
        BMC Ophthalmol. 2003; 3 (Oct 6): 10
        • Guzzardi D.G.
        • Teng G.
        • Kang S.
        • Geeraert P.J.
        • Pattar S.S.
        • Svystonyuk D.A.
        • Belke D.D.
        • Fedak P.W.M.
        Induction of human aortic myofibroblast-mediated extracellular matrix dysregulation: a potential mechanism of fluoroquinolone-associated aortopathy.
        J Thorac Cardiovasc Surg. 2019; 157 (Jan): 109-119.e2
        • Kaur K.
        • Fayad R.
        • Saxena A.
        • Frizzell N.
        • Chanda A.
        • Das S.
        • Chatterjee S.
        • Hegde S.
        • Baliga M.S.
        • Ponemone V.
        • Rorro M.
        • Greene J.
        • Elraheb Y.
        • Redd A.J.
        • Bian J.
        • Restaino J.
        • Norris L.B.
        • Qureshi Z.P.
        • Love B.L.
        • Brookstaver B.
        • Georgantopoulos P.
        • Sartor O.
        • Raisch D.W.
        • Rao G.
        • Lu K.
        • Ray P.
        • Hrusheshky W.
        • Schulz R.
        • Ablin R.
        • Noxon V.
        Bennett CL; southern network on adverse reactions (SONAR) project. Fluoroquinolone-related neuropsychiatric and mitochondrial toxicity: a collaborative investigation by scientists and members of a social network.
        J Community Support Oncol. 2016; 14 (Feb): 54-65
      1. FDA Briefing Document – Joint Meeting of the Antimicrobial Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. The benefits and risks of systemic fluoroquinolone antibacterial drugs for the treatment of acute bacterial sinusitis (ABS), acute bacterial exacerbation of chronic bronchitis in patients who have chronic obstructive pulmonary disease (ABECB-COPD), and uncomplicated urinary tract infections (uUTI). November 5,2015. https://www.pharmamedtechbi.com/~/media/Supporting%20Documents/The%20Pink%20Sheet%20DAILY/2015/November/Antimicrobial%20AC%20FDA%20briefing%2011515.pdf. Accessed September 27, 2019.

      2. PRAC recommendations on quinolone and fluoroquinolone use by the european union pharmacovigilance risk assessment committee. March 11, 2019. https://www.ema.europa.eu/en/documents/referral/quinolone-fluoroquinolone-article-31-referral-disabling-potentially-permanent-side-effects-lead_en.pdf. Accessed September 27, 2019.

        • Yu X.
        • Jiang D.S.
        • Wang J.
        • Wang R.
        • Chen T.
        • Wang K.
        • Cao S.
        • Wei X.
        Fluoroquinolone use and the risk of collagen-associated adverse events: a systematic review and meta-analysis.
        Drug Saf. 2019; 42 (Sep): 1025-1033
        • Noman A.T.
        • Qazi A.H.
        • Alqasrawi M.
        • Ayinde H.
        • Tleyjeh I.M.
        • Lindower P.
        • Bin Abdulhak A.A.
        Fluoroquinolones and the risk of aortopathy: a systematic review and meta-analysis.
        Int J Cardiol. 2019; 274 (Jan 1): 299-302
        • Rawla P.
        • El Helou M.L.
        • Vellipuram A.R.
        Fluoroquinolones and the risk of aortic aneurysm or aortic dissection: a systematic review and meta-analysis.
        Cardiovasc Hematol Agents Med Chem. 2019; 17: 3-10
        • Singh S.
        • Nautiyal A.
        Aortic dissection and aortic aneurysms associated with fluoroquinolones: a systematic review and meta-analysis.
        Am J Med. 2017; 130 (Dec, pp. 1449–57.e9)
        • Chui C.S.
        • Wong I.C.
        • Wong L.Y.
        • Chan E.W.
        Association between oral fluoroquinolone use and the development of retinal detachment: a systematic review and meta-analysis of observational studies.
        J Antimicrob Chemother. 2015; 70 (Apr): 971-978
        • Alves C.
        • Penedones A.
        • Mendes D.
        • Batel Marques F.
        A systematic review and meta-analysis of the association between systemic fluoroquinolones and retinal detachment.
        Acta Ophthalmol. 2016; 94 (Aug): e251-e259
        • Alves C.
        • Mendes D.
        • Marques F.B.
        Fluoroquinolones and the risk of tendon injury: a systematic review and meta-analysis.
        Eur J Clin Pharmacol. 2019; 75 (Oct): 1431-1443
        • Franklin J.M.
        • Schneeweiss S.
        When and how can real world data analyses substitute for randomized controlled trials?.
        Clin Pharmacol Ther. 2017; 102 (Dec): 924-933
        • Fusar-Poli P.
        • Radua J.
        Ten simple rules for conducting umbrella reviews.
        Evid Based Ment Health. 2018; 21 (Aug): 95-100
        • Niforatos J.D.
        • Weaver M.
        • Johansen M.E.
        Assessment of publication trends of systematic reviews and randomized clinical trials, 1995 to 2017.
        JAMA Intern Med. 2019; 179: 1593-1594
        • Moher D.
        • Liberati A.
        • Tetzlaff J.
        • Altman D.G.
        • PRISMA Group
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        BMJ. 2009; 339 (Jul 21): b2535
        • Ioannidis J.P.A.
        Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses.
        CMAJ. 2009; 181 (Oct 13): 488-493
        • Papatheodorou S.
        Umbrella reviews: what they are and why we need them.
        Eur J Epidemiol. 2019; 34 (Jun): 543-546
        • Ioannidis J.P.A.
        Meta-research: why research on research matters.
        PLoS Biol. 2018; 16 (Mar 13)e2005468
        • Shea B.J.
        • Reeves B.C.
        • Wells G.
        • Thuku M.
        • Hamel C.
        • Moran J.
        • Moher D.
        • Tugwell P.
        • Welch V.
        • Kristjansson E.
        • Henry D.A.
        AMSTAR 2: a critical appraisal tool for systematic reviews that include 23andomized or non-randomised studies of healthcare interventions, or both.
        BMJ. 2017; 358 (Sep 21): j4008
        • Bellou V.
        • Belbasis L.
        • Tzoulaki I.
        • Evangelou E.
        • Ioannidis J.P.
        Environmental risk factors and Parkinson's disease: an umbrella review of meta-analyses.
        Parkinsonism Relat Disord. 2016; 23 (Feb): 1-9
        • Altman D.G.
        • Bland J.M.
        How to obtain the P value from a confidence interval.
        BMJ. 2011; 343: d2304
        • VanderWeele T.J.
        • Ding P.
        Sensitivity analysis in observational research: introducing the E-value.
        Ann Intern Med. 2017; 167 (Aug 15): 268-274
        • Hill A.B.
        The environment and disease: association or causation?.
        Proc. R. Soc. Med. 1965; 58: 295-300
        • Schoenbach V.J.
        • Rosamund W.D.
        Relating risk factors to health outcomes.
        Understanding the fundamentals of epidemiology–an evolving text. Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, NC2000: 161-207
        • Degelman M.L.
        • Herman K.M.
        Smoking and multiple sclerosis: a systematic review and meta-analysis using the Bradford Hill criteria for causation.
        Mult Scler Relat Disord. 2017; 17 (Oct): 207-216
      3. FDAFDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics#targetText=%5B12%2D20%2D2018%5D,the%20body%2C%20called%20the%20aorta.&targetText=They%20can%20occur%20with%20fluoroquinolones,mouth%20or%20through%20an%20injection. Accessed October 11, 2019.

      4. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-advises-restricting-fluoroquinolone-antibiotic-use-certain. Accessed October 11, 2019.

      5. EMA. PRAC recommendations on signals. Adopted at the PRAC meeting of 10–13June2014. https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-10-13-june-2014_en.pdf. Accessed October 11, 2019.

      6. Health Canada Website. Summary safety review – oral fluoroquinolones – assessing the potential risk of retinal detachment. January 8, 2016. https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-oral-fluoroquinolones-assessing-potential-risk-retinal.html. Accessed October 11, 2019.

        • Potts J.
        • Genov G.
        • Segec A.
        • Raine J.
        • Straus S.
        • Arlett P.
        Improving the safety of medicines in the EU: from signals to action.
        Clin Pharmacol Ther. 2019; (Oct 17Epub ahead of print)https://doi.org/10.1002/cpt.1678
        • Brown A.
        • Wong J.R.
        • Kandiah S.
        • Moore J.
        • Quairoli K.
        Inappropriate fluoroquinolone use in academic and non-academic primary care clinics.
        J Gen Intern Med. 2019; (Jul 16)https://doi.org/10.1007/s11606-019-05157-6
        • Etminan M.
        • Sodhi M.
        • Ganjizadeh-Zavareh S.
        • Carleton B.
        • Kezouh A.
        • Brophy J.M.
        Oral fluoroquinolones and risk of mitral and aortic regurgitation.
        J Am Coll Cardiol. 2019; 74 (Sep 17): 1444-1450
        • Demetrious J.S.
        Spontaneous cervical artery dissection: a fluoroquinolone induced connective tissue disorder?.
        Chiropr Man Ther. 2018; 26 (Jul 9): 22
        • Del Zotto E.
        • Pezzini A.
        Use of fluoroquinolones and the risk of spontaneous cervical artery dissection.
        Eur J Neurol. 2019; 26 (Jul): 1028-1031
        • Bailey R.R.
        • Kirk J.A.
        • Peddie B.A.
        Norfloxacin-induced rheumatic disease.
        N Z Med J. 1983; 96: 590
        • Badal S.
        • Her Y.F.
        • Maher L.J.
        Nonantibiotic effects of fluoroquinolones in mammalian cells.
        J Biol Chem. 2015; 290 (Sep 4): 22287-22297
        • LeMaire S.A.
        • Zhang L.
        • Luo W.
        • Ren P.
        • Azares A.R.
        • Wang Y.
        • Zhang C.
        • Coselli J.S.
        • Shen Y.H.
        Effect of ciprofloxacin on susceptibility to aortic dissection and rupture in mice.
        JAMA Surg. 2018; 153 (Sep 1)e181804
        • Carino D.
        • Zafar M.A.
        • Singh M.
        • Ziganshin B.A.
        • Elefteriades J.A.
        Fluoroquinolones and aortic diseases: is there a connection.
        Aorta. 2019; 7 (Apr): 35-41
        • Tsai W.C.
        • Yang Y.M.
        Fluoroquinolone-associated tendinopathy.
        Chang Gung Med J. 2011; 34 (Sep-Oct): 461-467
        • Bisaccia D.R.
        • Aicale R.
        • Tarantino D.
        • Peretti G.M.
        • Maffulli N.
        Biological and chemical changes in fluoroquinolone-associated tendinopathies: a systematic review.
        Br Med Bull. 2019; 130 (Jun 19): 39-49
        • Wilton L.V.
        • Pearce G.L.
        • Mann R.D.
        A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies.
        Br J Clin Pharmacol. 1996; 41 (Apr): 277-284
        • Pickerill K.E.
        • Paladino J.A.
        • Schentag J.J.
        Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters.
        Pharmacotherapy. 2000; 20 (Apr): 417-428
        • Tomé A.M.
        • Filipe A.
        Quinolones: review of psychiatric and neurological adverse reactions.
        Drug Saf. 2011; 34 (Jun 1): 465-488
        • Zareifopoulos N.
        • Panayiotakopoulos G.
        Neuropsychiatric effects of antimicrobial agents.
        Clin Drug Investig. 2017; 37 (May): 423-437
        • Kommalapati A.
        • Wallam S.
        • Tella S.H.
        • Qureshi Z.P.
        • Bennett C.L.
        Fluoroquinolone-associated suicide.
        Eur J Intern Med. 2018; 55 (Sep): e21-e22
        • Sutter R.
        • Rüegg S.
        • Tschudin-Sutter S.
        Seizures as adverse events of antibiotic drugs: a systematic review.
        Neurology. 2015; 85: 1332-1341
        • Dolladille C.
        • Chrétien B.
        • Sassier M.
        • Fedrizzi S.
        • Alexandre J
        Fluoroquinolone and aortic dissection. Is it a class effect?.
        JACC. 2019; 73 (Jan 29): 382-383
        • Karageorgopoulos D.E.
        • Giannopoulou K.P.
        • Grammatikos A.P.
        • Dimopoulos G.
        • Falagas M.E.
        Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials.
        CMAJ. 2008; 178 (Mar 25): 845-854
        • Wang J.
        • Xu H.
        • Liu P.
        • Li M.
        Network meta-analysis of success rate and safety in antibiotic treatments of bronchitis.
        Int J Chron Obstruct Pulmon Dis. 2017; 12 (Aug 9): 2391-2405
        • Martin S.J.
        • Jung R.
        • Garvin C.G.
        A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
        Drug Saf. 2001; 24: 199-222
        • Lin L.
        • Chu H.
        • Murad M.H.
        • Hong C.
        • Qu Z.
        • Cole S.R.
        • Chen Y.
        Empirical comparison of publication bias tests in meta-analysis.
        J Gen Intern Med. 2018; 33 (Aug): 1260-1267